Akums Drugs and Pharmaceuticals Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on July 18, 2025
AKUMS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Akums Drugs and Pharmaceuticals has notified the exchanges about its 21st Annual General Meeting scheduled for Friday, July 18, 2025, at 11:00 am via Video Conference. The filing is accompanied by the company's first Integrated Annual Report for FY 2024-25, which also includes the Business Responsibility and Sustainability Report. The annual report highlights FY25 revenue of INR 4,118.20 Crores, Adjusted EBITDA of INR 512.73 Crores, and Profit After Tax of INR 343.80 Crores, alongside a net worth of INR 3,063.61 Crores and a net cash position of INR 566 Crores. It also notes a landmark EUR 200 million CDMO contract secured for the European market, listing on NSE and BSE in August 2024, and 14 state-of-the-art manufacturing facilities. The company claims to be India's largest homegrown CDMO with presence in over 70 countries.
Routine procedural filing, but useful for shareholders as it marks the first full-year annual report since the company's IPO in August 2024. Investors should review the integrated report for detailed financials and business strategy before the AGM, where voting on resolutions will take place.